Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions

Sanofi

Status and phase: Completed; Phase 4

Conditions: Hypertension; Dyslipidemia

Treatments: Drug: Ciprofibrate; Drug: Irbesartan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00350038

L_8759

Details and patient eligibility

About

The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.

Sex: All

Ages: 45 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hypertensive + dyslipidemic + damaged endothelial function

Exclusion criteria

• hepatic and kidney damage,
• IDDM (Insulin Dependent Diabetes Mellitus)
• Freckson V type hyperlipoproteinaemia

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)